CSF1R and central nervous system cancer: Anti-CSF-1R therapy by using CSF-1R inhibitors alone, such as PLX3397 (Plx, i.e., Pexidartinib) prominently extends animal survival, including long-term survival in previous preclinical glioma/GBM mouse models [18, 19], which are far away from the results of anti-CSF-1R monotherapy in GBM clinical trials [44].